convertibleCAR

**convertibleCAR** is a modular **CAR-T cell therapy platform** developed by **Xyphos Biosciences** and advanced within **Astellas Pharma**. The platform engineers patient or donor T cells to express a chimeric antigen receptor built around an inert form of the human **NKG2D extracellular domain** called **iNKG2D**. These convertibleCAR-T cells are designed to remain functionally controllable and are activated only in the presence of proprietary bispecific adapter molecules known as **MicAbodies**, which fuse an iNKG2D-selective ULBP2-derived ligand to an antigen-binding antibody. This architecture allows the same CAR-T cell product to be redirected to different tumor or infected-cell antigens by changing the adapter, potentially improving dosing control, multiplex targeting, and retargeting compared with conventional single-antigen CAR-T therapies. The platform has been explored in oncology, including hematologic malignancies and solid tumors, and has also been described in HIV eradication strategies aimed at reducing the latent HIV reservoir.

Other names

iNKG2D CAR-T cellsiNKG-2D CAR-T cellsiNKG 2D CAR-T cellsconvertibleCAR-T cells